Universität Augsburg

University / College


Location: Augsburg, Germany (DE) DE

ISNI: 0000000121089006

ROR: https://ror.org/03p14d497

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Recordings of digital media life: Advancing (qualitative) media diaries as a method (2022) Wagner A, Schwarzenegger C, Gentzel P Journal article The "Seminartage Weiterbildung Allgemeinmedizin" (SemiWAM (R)) - development, implementation and evaluation of a five-year, competence-based postgraduate programme in Bavaria (2022) Roos M, Schneider A, Gensichen J, Simmenroth A, Kühlein T, Schneider D Journal article Lernberatung in Lernentwicklungsgesprächen: Wie werden Schüler*innen einbezogen? (2022) Kücherer B, Ertl S, Hartinger A Journal article Partizipation von Schüler*innen in bayerischen Lernentwicklungsgesprächen (2022) Hartinger A, Ertl S, Kücherer B Book chapter / Article in edited volumes IgG4-related pseudotumours: a series of 12 cases and a review of the literature (2022) Maccagno A, Grosser B, Füzesi L, Konukiewitz B, Vlasenko D, Weckermann D, Raab S, et al. Journal article First report from the German COVID-19 autopsy registry (2022) von Stillfried S, Bülow RD, Röhrig R, Boor P, Böcker J, Schmidt J, Tholen P, et al. Journal article Berücksichtigung individueller Lernprozesse in Lernentwicklungsgesprächen (2022) Ertl S, Kücherer B, Hartinger A Book chapter / Article in edited volumes Lernentwicklungsgespräche und die Entwicklung motivationaler Aspekte des Lernens (2022) Ertl S, Kücherer B, Hartinger A Journal article, Original article An Evaluation of Speech-Based Recognition of Emotional and Physiological Markers of Stress (2021) Baird A, Triantafyllopoulos A, Zänkert S, Ottl S, Christ L, Stappen L, Konzok J, et al. Journal article Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, et al. Journal article